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Abstract
Slow coronary flow is an angiographic phenomenon characterized by delayed opacification of
vessels in the absence of any evidence of obstructive epicardial coronary disease. In this article,
we present serious clinical manifestations of extremely slow coronary flow in two hypertensive
patients with preserved ejection fraction in echocardiographical examination: a 57 year-old
woman with acute coronary syndrome and temporary ST elevation; and a 65 year-old man
with atrial tachycardia which was leading to sudden arrest of circulation.
The woman was admitted to hospital due to recurrent syncope and chest pain. Because of
severe bradycardia, an AAI pacemaker was implanted. Coronary angiography without evident
obstructive lesion revealed extremely slow flow of dye through arteries.
The man was admitted to hospital because of heart palpitations (paroxysmal atrial tachycar-
dia, PAT) followed by chest pain. During hospitalization, a sudden arrest of circulation in the
course of supraventricular tachycardia of 220/min with atrioventricular conduction of 1:1
occurred. Coronary arteriography did not show any occlusions in the coronary arteries, al-
though extremely slow dye flow was seen. Electrophysiological examination revealed arrhyth-
mia of the left atrial (PAT) (tricuspid valve anulus mapping) without induced ventricular
arrhythmia. Because of symptomatic bradyarrhythmia, a VVI heart pacemaker was implanted.
Over a 12-month observation, his heart rate remained under control, and the patient did not
complain of chest pains or heart palpitations. (Cardiol J 2009; 16, 5: 462–468)
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Introduction
Slow coronary flow (SCF) is a phenomenon
detected by angiographic examination of coronary
arteries. It is characterized by slow velocity flow of
dye through the coronary artery in the absence of
any evident obstructive lesion in it. The phenome-
non was first described by Tembe et al. in 1972 [1].
Classic SCF does not include the re-flow and slow
re-flow phenomena which are observed during an-
gioplasty, slow flow velocity of dye in ecstatic ves-
sels, cardiomyopathy, connective tissue disorders
and other disorders which may have an impact on
the flow in microcirculation [2].
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Furthermore, SCF is not a part of the cardio-
logical X syndrome, but constitutes a separate dis-
ease entity, although both phenomena show disor-
ders in microcirculation. However, in cardiological
X syndrome, there is no slow flow velocity of dye
in coronary vessels [2]. Many researchers empha-
size the influence of SCF on the electrical disorders
of the heart with the tendency for rhythm disorders.
This article presents two cases of patients
with extremely slow coronary flow, manifested
clinically by acute coronary syndrome with tem-
porary ST segment elevation, and in the second
case by atrial tachycardia leading to sudden arrest
of circulation.
Case 1
Case 1 is of a 57 year-old woman (registration
number 12549/07) suffering from arterial hyperten-
sion, alcohol abuse and Parkinson’s disease. She has
undergone cholecystectomy because of nephroli-
thiasis. In the past, she suffered from acute pancre-
atitis and had kidney cysts. She was admitted to hos-
pital due to recurrent syncope, paroxysmal dysp-
noea and pain in the chest. Electrocardiography
revealed sinus bradycardia of 40 beats/min with no
changes in ST segment. Echocardiographic (ECG)
examination demonstrated left ventricular muscle
hypertrophy of 14 mm, without segmental disorders
in contractility, with normal ejection fraction of left
ventricle (approximately 59%) and with normal
valves. A 24-hour Holter electrocardiography moni-
toring revealed sinus node dysfunction with symp-
tomatic sinus bradycardia with a rate below
40 beats/min during waking hours. Premature su-
praventricular beats (2 786/24 h) were registered
without atrioventricular conduction disturbances.
Sick sinus syndrome with decreased cerebral
blood flow was diagnosed. Indications for permanent
atrial pacing were determined and an atrial-inhibit-
ed pacing system (AAI) was implanted. Five days
after the operation, in the morning, the patient felt
an acute 20-minute pain in the chest followed by
hypotonia and fainting accompanied by 2 mm
ST elevation in ECG above the inferior wall and re-
ciprocal changes of ST segment in the leads: I, AVL
and V1–V3 (ST depression to 1.5 mm) (Fig. 1). The
coronary arteriography performed immediately did
not show any atherosclerotic occlusions. At the
same time, however, extremely slow flow of dye
through the coronary arteries was detected. TIMI
frame count for the left anterior descending coro-
nary artery was 62.4 ± 3.5 frames (reference value
36.2 ± 2.6) and of the right coronary artery 58.8 ±
± 3.1 (reference value 20.4 ± 3) [3]. There was no
increase in the serum markers of cardiac damage
and no evolution in ST-T segment of the ECG
record was observed. Therapy with antiplatelet
agents (aspirin and clopidogrel) as well as the angi-
otension converting enzyme inhibitor, amlodipine
and statine was performed. During a 12-month fol-
low-up the patient was well with no complaints. No
chest pain or syncope were observed.
Figure 1. Electrocardiogram in the female patient during chest pain. ST elevation in II, III, avF leads and reciprocal
changes of ST segment in the leads: I, AVL and V1–V3 (ST depression to 1.5 mm).
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Case 2
Case 2 is of a 65 year-old man (registration
number 12783/08) suffering from arterial hyperten-
sion, insulin treated diabetes and the symptoms of
obstructive sleep apnea. He was admitted to the
Cardiology Department because of heart palpita-
tions followed by exercise-related pain in the chest.
The ECG record showed paroxysmal atrial tachy-
cardia (PAT) 210 beats/min with changing relation-
ship (2:1, 3:1, 4:1) between P waves and QRS com-
plexes and average ventricular rate of approximate-
ly 70 beats/min (Fig. 2). Laboratory findings showed
a minimal increase in troponin T concentration,
normal concentration of creatine kinase (CK-MB),
dyslipiemia (lower concentration of HDL cholesterol,
increased concentration of triglycerides and normal
concentration of total cholesterol and LDL choles-
terol — the patient was undergoing treatment with
statine). The concentration of glycosylated hemo-
globin reached the level of 8.4%, which testified to
the lack of diabetes control in the last three months.
The level of thyrotrophic hormone and inflamma-
tory parameters (blood sedimentation rate and pro-
tein level) was normal. A chest X-ray showed symp-
toms of liquid retention at the bottom of the lungs
and revealed enlargement of the heart chambers.
Echocardiography examination demonstrated dila-
tation of the left atrium and right ventricle, and
hypertrophy of the left ventricular muscle. Ejection
fraction of the left ventricle was about 50% with-
out disorders in segmental myocardial contractili-
ty but with impaired diastolic relaxation. The mor-
phology and the function of the valves were normal.
The coronary arteriography did not show any oc-
clusions in coronary arteries, although extremely
slow dye flow velocity was seen. Thrombolysis in
Myocardial Infarction (TIMI) frame count for the left
anterior descending coronary artery was 66 ± 2.1 fra-
mes (reference value 36.2 ± 2.6) and for the left
circumflex coronary artery 44.4 ± 3.7 (reference
value 22.2 ± 4.1) [3]. The right artery was reces-
sive. On the fifth day of hospital treatment, a sudden
arrest of circulation in the course of supraventricular
tachycardia of 220/min with atrioventricular conduc-
tion of 1:1 (Fig. 3) occurred, which was brought
under control by resuscitation and the use of amio-
darone. The patient underwent electrophysiologi-
cal examination which testified to the arrhythmia
of the left atrial (PAT) in the mapping of tricuspid
ring without induced ventricular arrhythmia. An
ablation of atrioventricular junction was considered.
Due to the occurrence of obstructive sleep apnea,
the patient underwent spirometrical and polisomno-
graphic examination which testified to the presence
of central apnea. The treatment included continu-
ous positive airway pressure and produced satisfac-
tory clinical results. Because of numerous serious
hemodynamic tachycardia with rapid increase of the
Figure 2. The electrocardiogram record (male patient) with paroxysmal atrial tachycardia 210 beats/min with
relationship between P waves and QRS complexes 3:1 and ventricular rate of approximately 70 beats/min.
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heart rate, caused by slight physical exercise, the
treatment included the use of amiodarone and
carvedilole. A good control of ventricular rate was
observed during the atrial tachycardia, but on the
other hand, temporary periods of symptomatic slow
heart rate (to 40–50 beats/min) were observed.
Because of the need for antiarrhythmic preventive
treatment to increase atrioventricular block and
decrease the ventricular rate for the patient with
the sinus node dysfunction, a VVI heart pacemaker
was implanted. Pharmacological treatment includ-
ed the use of antiplatelet agents, statine, angio-
tensin converting enzyme inhibitor, carvedilole,
verapamile and anticoagulants. During the eight-
month observation, a good control of heart rate was
observed (during Holter ECG monitoring, the aver-
age ventricular rate control during PAT was
71/min, maximum 109//min with frequent periods of
ventricular stimulation of 60/min). The ablation of the
atrioventricular junction was finally not performed.
Good control of blood pressure and glycemia was
achieved, and the patient did not complain of chest
pains or heart palpitations.
Discussion
Both these cases with their dramatic clinical
manifestations have one thing in common. Despite
a normal coronary angiogram in patients with typi-
cal anginal symptoms, delay of opacification of co-
ronary arteries in coronary angiography was ob-
tained. The etiopathogenesis of SCF is complicat-
ed and not yet fully understood. It is believed that
some genetic and metabolic factors as well as mi-
crocirculation disorders, endothelium dysfunction,
disseminated process of atherosclerosis as well as
inflammation contribute to its occurrence [4].
Both our patients manifested risk factors con-
nected with the process of arteriosclerosis, the
cause of which is endothelial dysfunction. The wom-
an suffered from arterial hypertension, the man
from hypertension, diabetes, dyslipidemia and ob-
structive sleep apnea. Intravascular ultrasound to
examine intima-media complex, small atheroma-
tous plaques not detected by angiographic exami-
nation, measurement of coronary flow reserve or
pressure gradient after adenosine administration,
would allow for a more precise examination of the
condition of the vessels and exclusion of their pa-
thology. These two patients underwent only cor-
onarography without the above-mentioned exami-
nations, although in the future such examinations
may prove extremely valuable in the cases of sig-
nificantly slow coronary flow.
In examining genetic disorders in patients with
SCF, Cakmak et al. [5] concluded that thickening
of the intima-media complex of the neck artery oc-
curs with the presence of D allele in the genotype
of angiotensin converting enzyme, which, indirect-
ly, testifies to the changes in coronary vessels of
Figure 3. Supraventricular tachycardia of 220/min with atrioventricular conduction of 1:1 with sudden arrest of circulation.
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the same character. Meanwhile Nurcalem et al. [6]
claims that endothelial nitric oxide synthase gene
polymorphism (T-786C) may constitute another
risk factor.
Some role in the etiopathogenesis of the phe-
nomenon, as claimed by Beltram et al. [7], may be
played by a chronic increase in coronary microcir-
culation passive tone. Among other causes of SCF,
a microvascular spasm detected after the applica-
tion of contrast may trigger contraction [8]. SCF is
also characterized by the increased tendency of
platelets to aggregate, examined by test with ris-
tocetin, collagen and ADP [9].
In terms of metabolic disorders in SCF, partic-
ular attention is paid to the role played by the thy-
roid hormones and the level of homocysteine. Thy-
roid hormones influence the level of plasma con-
centration of homocysteine as well as causing
higher resistance in microcirculation. Research by
Evrengul et al. [10] suggests that thyroid hormones
and/or the disorders in their metabolism may be
responsible for the increase in the level of plasma
homocysteine in patients suffering from SCF. An-
other examination testified to the lower level of folic
acid in plasma in patients with increased level of
homocysteine [11]. Work by Nurkalem et al. [12]
points to the more frequent occurrence of clinical-
ly open resistance to insulin in patients with SCF.
Despite the lack of clinical features that would
be typical of SCF, common symptoms include par-
oxysmal angina pectoris and fainting connected with
rhythm disorders (e.g. atrial fibrillation or ventricu-
lar tachycardia) and conduction disturbances [2, 13].
Our two patients manifested symptoms of angina
pectoris and both suffered from sinus node insuffi-
ciency which required the implantation of a stimu-
lator. The man suffered from attacks of supraven-
tricular arrhythmia in the form of atrial tachycar-
dia. Most probably, endothelial dysfunction, slow
coronary flow with the conduction of 1:1 with atrial
tachycardia and fast function of ventricles caused
loss of consciousness and sudden circulatory arrest.
A usually not life-threatening arrhythmia constitut-
ed in this case a direct threat to life.
Among the pathologies of the SCF detected by
electrocardiography, particular attention is paid to
the longer P-wave duration and a greater difference
between maximum and minimum P-wave duration,
which may be caused by ischemia in terms of mi-
crocirculation and/or changes in the regulation of
the vascular system caused by the autonomous
nervous system [14, 15]. The same mechanism may
be responsible for the increase in dispersion of QT
interval which reflects the differences in repolariza-
tion time in some areas of the atrium and its electric
instability. It has been proved that the dispersion
of QT interval changes during myocardial ischemia
episodes. It is also claimed that SCF is connected
with the prolongation of QT segment or the increase
in QT dispersion [16, 17].
Patients with SCF suffer more frequently from
paroxysmal atrial fibrillation, changes in ST-T seg-
ment and conduction disturbances during resting
ECG. Exercise tests in patients with SCF are posi-
tive in about 20% of cases [18, 19].
The main diagnostic method for SCF is coro-
narography. In both our cases, angiography of coro-
nary arteries was performed. The examination was
performed immediately, due to the symptoms of
acute coronary syndrome or effort angina pectoris.
Gibson method was applied to assess SCF and the
results testified to significant SCF [20].
A method proposed by Gibson (TIMI frame
count) [3] is also useful for detecting SCF. The
method counts the number of frames of angiograph-
ic record from the moment of the appearance of dye
in the artery opening to a given place in a distal
section of the vessel. The flow within the vessel is
considered slow when the TIMI frame count ex-
ceeds the norm twice, i.e. for the anterior coronary
artery 41 frames, for the circumflex artery and right
coronary artery 27 frames, in the standard angio-
graphic record [3]. Other useful examinations in-
clude the measurement of fractional flow reserve
and intravascular ultrasound [21–23]. The latter is
an examination which detects a very small narrow-
ing, so it can be used to detect small arteriosclero-
sis focuses not registered by conventional angio-
graphic examination. As we said before, the com-
mon angiography examination does not include the
above-mentioned examinations, although they
prove extremely valuable in the diagnosis of SCF.
Cin et al. [24], using FFR and intravascular ultra-
sound methods, managed to prove the occurrence
of scattered narrowings and calcification along the
walls of coronary vessels as well as the presence
of plaques which do not change the lumen of coro-
nary vessels in coronarography in patients with
SCF. Additionally, they claim that the patients have
a significant pressure gradient between the initial
and final sections of epicardial coronary artery. The
authors concluded that SCF may take the form of
scattered arteriosclerosis comprising both micro-
circulation and epicardial arteries [24].
It needs to be stressed that the medicines that
stabilized the clinical state and, following lengthy
use, resulted in a significant improvement in the
female patent, were those from the group of calcium
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antagonists, as well as angiotensin convertase
inhibitors and statine, whereas in the male patent
significant improvement was visible after the ad-
ministration of continuous positive airway pressure,
proper glycemia control, the control of a part of the
ventricles by means of carvedilole and, as in the fe-
male patient, the administration of calcium antago-
nists, angiotensin convertase inhibitor and statine.
Symptomatic drugs used in coronary arterial dis-
ease do not bring significant relief in SCF. Nitro-
glycerine does not reduce anginal pain because it
does not have any impact on the small section ves-
sels and does not improve microcirculation, which
is the main cause of SCF [2]. Positive effects are
observed after the application of dipyridamole which
inhibits reabsorption and decomposition of adenosine,
which loosens resistance arterioles [12]. Calcium
antagonists (niphedypine) may also be beneficial.
Vascular spasm receded after the use of verapamil
or adenosine [2]. The use of 40 mg simvastatin for
six months led to some improvement regarding my-
ocardium perfusion in patients with SCF [5]. Topal
et al. [25] administered 20 mg trimetazidin three
times per day for four weeks to patients with slow
coronary flow. They observed increased heart rate
variability and increased levels of endoteline-1 and
nitric oxides and, clinically, a smaller number of
angina pectoris episodes. Heart rate variability cor-
related negatively with the level of endoteline-1 and
positively with nitric oxide.
The prognosis for patients with SCF in coro-
nary vessels is generally favourable, although at
times the health discomforts may become strong-
er and occasionally there might be an acute coro-
nary incident. Due to increased QT dispersion, the
most serious complication connected with SCF may
be sudden death caused by malignant ventricular
arrhythmia [13].
An important pathology that has been detect-
ed and diagnosed in our patients was SCF. It seems
that arterial hypertension separately, or together
with diabetes and obstructive sleep apnea, were the
factors influencing most strongly endothelial dys-
function, which strengthened the phenomenon of
SCF and its consequences. Some authors suggest
that microcirculation and endothelial function is
impaired in people with SCF [5, 6]. The condition
of microcirculation in our two patients was undoubt-
edly influenced by diseases such as arterial hyper-
tension, diabetes, obstructive sleep apnea or alco-
hol abuse. The list of symptoms and cardiological
complications of obstructive sleep apnea is long.
Due to frequent episodes of anoxia, heart rate may
increase and there might be disturbances in heart
rhythm and conduction as well as episodes of acute
coronary incidents, increases in arterial blood pres-
sure, blood stroke or pulmonary hypertension. Cir-
culation complications are the main cause of deaths
in the case of obstructive sleep apnea, with men
aged 50 and above running the greatest risk [26].
In the case of prolonged apnea, the risk of ventricu-
lar and supraventricular rhythm disorders and con-
duction disturbances is higher. According to Gar-
rigue’s register, 68% of patients qualified for con-
tinuous stimulation have previously undetected
obstructive breathing disorders, and 20% of patients
with acute apnea suffer from significant hemody-
namic conduction disturbances [27]. Also in patients
with the symptoms of angina pectoris, obstructive
sleep apnea occurs twice as frequently as in other
patients. Recurring significant hypoxemia, acidosis,
increased arterial blood pressure and sympathicot-
onia with recurrent changes in intramural heart
pressure and changes inside the chest caused by
apnea lead to the dysfunction of the endothelium
which is the basis of SCF, and in the long term, to
the damage of coronary vessels. It has been proved
that treatment which creates positive pressure in
air passages lead to fewer rhythm disorders and
coronary stabilization [28]. The problem of SCF
deserves more attention, especially in patients with
no other pathologies which could be responsible for
a serious clinical state detected. SCF requires prop-
er diagnosis and treatment.
Conclusions
Slow coronary flow may be associated with se-
rious cardiovascular events and clinically manifests
with chest pains, arrhythmia and conductibility
disorders. Adequate control of cardiac rhythm,
blood pressure, glycemia, any obstructive breath-
ing disorders, treatment with antiplatelet agents,
statine, angiotensin converting enzyme inhibitor, all
bring relief for the patients and maintain improve-
ment.
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